Takeda Showcases Late-Stage Pipeline Advancing Breakthrough Therapies Across Key Areas

Takeda will host an investor R&D Day today at 8:30 a.m. JST in Tokyo. The event will highlight the company’s late-stage programs, their potential benefits for patients, and the market opportunities they offer.

Christophe Weber, Takeda chief executive officer, said in a statement, “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products. The first three Phase 3 programs will be read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.”

Takeda plans eight regulatory filings between FY2025 and FY2029, highlighting its promising late-stage pipeline. Key programs include oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999), and elritercept (TAK-226), with combined peak revenue potential of $10B - $20B. Phase 3 data from three programs are expected in 2025:

• Oveporexton (oral orexin receptor 2 agonist) for narcolepsy type 1

• Zasocitinib (oral TYK2 inhibitor) for psoriasis

• Rusfertide (injectable hepcidin mimetic) for polycythemia vera

  
  

Regulatory filings for these are planned for FY2025 and 2026. Five additional filings are set for FY2027-2029, including:

• Zasocitinib for psoriatic arthritis

• Mezagitamab for immune thrombocytopenia (ITP) and IgA nephropathy (IgAN)

• Fazirsiran for alpha-1 antitrypsin deficiency liver disease (AATD-LD)

• Elritercept for anemia in hematologic cancers, with a partnership with Keros Therapeutics for global development.

  
  

“Takeda has established an exciting, late-stage pipeline of transformative therapies that we believe will deliver value to our company and, most importantly, to the patients we serve across the world. As we continue scaling our capabilities and maximizing R&D investment to deliver the late-stage pipeline, we are also progressing an exciting early-stage pipeline, supporting a cutting-edge research organization, and focusing on creative business development across our therapeutic areas to sustain Takeda’s future and continue to meet significant unmet patient needs,” stated Andy Plump, president of R&D at Takeda.

The 2024 R&D Day agenda includes the following presentations and speakers:

• A Global, Innovation-Driven Biopharmaceutical Company - Christophe Weber, President & CEO

  
  

• R&D Strategy and Pipeline Highlights - Andy Plump, President, Research and Development

  
  

• Neuroscience: Deep-Dive on Orexin Franchise - Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit and Head of Global Development, Ramona Sequeira, President of Global Portfolio Division

  
  

• Gastrointestinal and Inflammation: Deep-Dive on Zasocitinib, Rusfertide, Mezagitamab, Fazirsiran - Chinwe Ukomadu, Head of Gastrointestinal and Inflammation Therapeutic Area Unit, Ramona Sequeira, President of Global Portfolio Division

  
  

• Oncology: Deep-Dive on Elritercept – Newly Announced Business Development Deal - Teresa Bitetti, President Global Oncology Business Unit, P.K. Morrow, Head of Oncology Therapeutic Area Unit

  
  

Webcast Details: The live webcast began at 8:30 a.m. JST on December 13 (6:30 p.m. EST, December 12). Presentations were available on Takeda’s Investor Relations website, with a video replay provided after the meeting.